TNF and rheumatoid arthritis: Tocilizumab, an IL-6 receptor antagonist, was evaluated in a 24-week placebo-controlled randomized trial (RADIATE) in RA patients who demonstrated an inadequate response to one or more anti-TNF therapies and showed that the tocilizumab group had a better ACR20 response compared with the placebo group [29].